Benralizumab was launched in 2018 following regulatory approval in Canada and is now widely available for Canadian patients with severe eosinophilic asthma.~This study is an observational cohort study of patient reported outcomes (PROs) within real-world settings for participants who are prescribed benralizumab for treatment of uncontrolled severe eosinophilic asthma. Patients will be recruited in select clinics across Canada.~Survey data for each participant in the study will be obtained at the following time-points:~Baseline (Week 0)~Short-term follow up: 1-, 2-, 4-, and 8-weeks after baseline~Long-term follow-up: 24- and 56-weeks after baseline
This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.